Group 1 - 德方纳米 plans annual equipment maintenance to ensure efficient and stable operation, starting January 1, 2026, for one month, with no significant impact on 2026 performance [1] - 达意隆's subsidiary Tianjin Baolong faces a significant decline in OEM orders due to strategic adjustments from core customers, leading to plans to shut down production lines [2] - 天威视讯's subsidiary plans to transfer project assets for 604.3 million yuan to a related party, constituting a related transaction [3] Group 2 - 金龙羽 intends to sign a strategic cooperation framework agreement with an investment institution to establish an industrial merger fund with a planned scale of 1.5 billion yuan [4] - 紫光国微's subsidiary plans to establish a new company with multiple partners, including a subsidiary of CATL, with a registered capital of 300 million yuan [5] - 信隆健康's major shareholder plans to reduce its stake by up to 1% through trading [6] Group 3 - 龙建股份 wins a 612 million yuan EPC contract for a project, which represents approximately 3.27% of the company's audited revenue for 2024 [7] - 复旦张江 receives acceptance for a clinical trial application for a drug aimed at visualizing malignant lesions in lung cancer patients [9] - 博实股份's major shareholder plans to reduce its stake by up to 2.93% [10] Group 4 - 百纳千成 plans to acquire 100% of Zhonglian Century's shares to expand its marketing business and digital advertising solutions [11] - 天铁科技's major shareholder is under criminal detention, but the investigation is unrelated to the company's operations [12] - 海看股份's shareholder plans to reduce its stake by up to 3.6% [13] Group 5 - 智光电气's subsidiary signs a procurement contract worth 148 million yuan for a high-voltage energy storage system [14] - 西藏矿业's attempt to transfer 100% of a subsidiary's equity has not attracted qualified buyers, leading to automatic withdrawal from the trading platform [15] - 英诺激光's major shareholder plans to reduce its stake by up to 3% [16] Group 6 - 福鞍股份's major shareholder plans to reduce its stake by up to 3% [17] - 白云山 receives a drug registration certificate for a rabies vaccine [18] - 华电科工 signs a contract worth approximately 265 million yuan for a power plant project [19] Group 7 - 康弘药业 receives a drug registration certificate for a medication used to treat schizophrenia [20] - 西菱动力's actual controller plans to reduce their stake by 2% [21] - 海希通讯's actual controller plans to reduce their stake by 0.48% [22] Group 8 - 海南机场 plans to transfer 90% of a subsidiary's equity for approximately 500 million yuan, expecting a profit of about 200 million yuan from the transaction [23] - 森远股份 signs a contract for a computing cluster integration project worth 26.78 million yuan [24] - 丽珠集团's subsidiary receives acceptance for a drug registration application for a new treatment for psoriasis [25] Group 9 - 郑州银行 plans to acquire a village bank and convert it into a branch [26] - 方正证券 announces a cash dividend distribution plan for the third quarter of 2025 [27] - 金陵体育 announces a cash dividend distribution plan for the first three quarters of 2025 [29] Group 10 - 紫金银行 announces a mid-term profit distribution plan for 2025 [30] - *ST建艺's major shareholder waives 1.4 billion yuan in debt and donates 400 million yuan to support the company [31] - 万朗磁塑's major shareholder plans to reduce their stake by up to 3% [32] Group 11 - 艾力斯's core product is included in a list of potential breakthrough therapies for lung cancer [33] - 富创精密's shareholder plans to transfer 918.63 million shares [34] - 东阳光's subsidiary plans to increase capital and introduce investors [35] Group 12 - 侨银股份 plans to acquire a 16.67% partnership in a venture capital fund [36] - 尤夫股份 receives a government subsidy of 4.04 million yuan for a technical improvement project [37] - 倍轻松 and its actual controller are under investigation for information disclosure violations [38] Group 13 - 万润新能 plans to reduce production on some lines for maintenance, expecting a reduction of 5,000 to 20,000 tons in lithium iron phosphate output [39]

Market Performance - Major market indices opened with mixed results, with the Shanghai Composite Index down 0.05% at 3957.83 points, the Shenzhen Component Index up 0.06% at 13539.05 points, and the ChiNext Index down 0.21% at 3232.41 points [1] Individual Stock Performance - A total of 1901 stocks rose at the open, with 22 stocks hitting the daily limit up, including Victory Energy with 11 consecutive limit ups, Jiamei Packaging with 9 limit ups in 11 days, and Shenjian Co. with 7 consecutive limit ups [1] - Conversely, 2553 stocks declined at the open, with notable declines from Sunflower, Jiangtian Technology, and Beikong [1] Price Continuity Statistics - Among stocks that hit the limit up yesterday, 16 stocks, including Shenjian Co. and Fenglong Co., continued to hit the limit up today [1] - Stocks that opened lower included Guangdao Tui, Tianyuan Co., and Hengda New Materials, with declines of 6.43%, 5.71%, and 4.32% respectively [1]

公开信息显示，倍轻松2022—2024年年报、2025年半年报，都曾收到过上交所信披监管问询函。 【涉嫌信披违法违规 倍轻松及实控人被证监会立案】倍轻松（688793.SH）12月25日晚间公告，公司及 实际控制人马学军分别于当日收到证监会下发的《立案告知书》。因公司及马学军涉嫌信息披露违法违 规，证监会决定对公司及马学军立案。 公告称，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关 工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 据倍轻松2025年11月20日披露的《简式权益变动报告书》，当日，马学军通过询价转让减持2552579股 人民币普通股股份，占公司总股本的2.97%。本次权益变动后，马学军持股比例降至37.51%。中经记者 孙汝祥 夏欣 北京报道 ...

倍轻松(688793)26日盘中大幅跳水，截至发稿，该股跌约11%。 公告称，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关 工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 公司25日晚间公告，12月25日收到中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知 书》，以及对实际控制人马学军下发的《立案告知书》，因公司及实际控制人马学军涉嫌信息披露违法 违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对 公司及实际控制人马学军立案。 ...

Group 1 - The core point of the article is that the leading portable massager company, Beiqingsong (688793.SH), experienced a significant drop of 11%, reaching a new annual low of 23.56 yuan, with a total market value of 2.03 billion yuan [1] - Beiqingsong announced that the company and its actual controller, Ma Xuejun, received a "Notice of Investigation" from the China Securities Regulatory Commission (CSRC) on December 25, 2025, due to suspected violations of information disclosure laws [1] - Ma Xuejun has also proposed a share reduction plan, intending to transfer 2.5526 million shares, which accounts for 2.97% of the total share capital [1]

Core Viewpoint - Shenzhen Beiqing Song Technology Co., Ltd. (stock code: 688793) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to legal claims from affected investors [1][2][3]. Group 1: Company Announcement - On December 25, 2025, Beiqing Song announced that it received a notice of investigation from the CSRC due to alleged violations by the company and its actual controller, Ma Xuejun [1][2]. - The CSRC's decision to initiate an investigation is based on the provisions of the Securities Law and the Administrative Penalty Law of the People's Republic of China [1][2]. Group 2: Legal Implications for Investors - Investors who suffered losses due to alleged false statements by Beiqing Song may file claims for compensation, which can include losses from price differences, commissions, and stamp duty [3][4]. - According to the latest judicial interpretation, investors holding Beiqing Song shares as of the market close on December 25, 2025, are eligible to seek compensation [2][3]. - The conditions for claims will be adjusted based on the conclusions of the CSRC's investigation, with final determinations made by the court [4]. Group 3: Legal Representation - Lawyer Li Jian from Zhejiang Yufeng Law Firm, who has successfully represented investors against over 130 listed companies, emphasizes the potential for legal action against Beiqing Song [3][4]. - Investors seeking compensation must provide necessary documentation, including securities account information and transaction records [4].

Group 1 - The company and its actual controller, Ma Xuejun, are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2] - The company announced that its business operations are currently normal and it will cooperate with the CSRC during the investigation [2] - The company specializes in the design, research and development, production, sales, and service of smart portable massagers, with its main products being eye and neck massagers [2] Group 2 - The company has faced significant financial pressure, reporting net losses of 124 million yuan in 2022 and 50.87 million yuan in 2023, with a brief profit of 10.25 million yuan in 2024 before returning to losses [3] - For the first three quarters of 2025, the company reported revenue of 552 million yuan, a year-on-year decline of 34.07%, and a net loss of 65.63 million yuan, a year-on-year increase in losses of 600.98% [3] - The company has been under regulatory scrutiny regarding the authenticity of its business operations, including inquiries into product sales, pricing, and financial transactions involving its actual controller [3][4]

截至2025年12月25日收盘，倍轻松(688793)报收于26.5元，上涨0.26%，换手率0.63%，成交量5396.0 手，成交额1426.23万元。 当日关注点 交易信息汇总 资金流向 12月25日主力资金净流入124.18万元；游资资金净流入54.69万元；散户资金净流出178.87万元。 公司公告汇总 关于涉及诉讼的公告 深圳市倍轻松科技股份有限公司及子公司北京倍轻松科技开发有限公司收到北京知识产权法院送达的 《民事起诉状》，原告大东电机工业株式会社以侵害发明专利权纠纷为由提起诉讼，涉案金额为1000万 元人民币。公司为被告一，案件已立案但尚未开庭审理。原告诉请判令两被告停止侵权行为、销毁模具 与库存产品，并赔偿经济损失及合理费用。公司表示被诉产品非核心或主要营收产品，经营未受实质性 影响，案件最终判决结果尚不确定，公司将依法维护权益并及时披露进展。 关于收到中国证券监督管理委员会立案告知书的公告 来自交易信息汇总：12月25日主力资金净流入124.18万元，散户资金呈净流出态势。 来自公司公告汇总：倍轻松及子公司因涉嫌侵害发明专利权被大东电机起诉，涉案金额1000万 元。 来自公司公告汇总：公司 ...

12月25日晚间，倍轻松（688793）发布公告称，公司于2025年12月25日收到中国证监会下发的《立案告知书》，以及对实际控制人 马学军下发的《立案告知书》，因公司及实际控制人马学军涉嫌信息披露违法违规，根据相关法律法规，中国证监会决定对公司及 实际控制人马学军立案。 公司表示，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关工作，并严格按照相关法 律法规和监管要求及时履行信息披露义务。 公开资料显示，倍轻松是一家专注于健康产品创新研发的高新技术企业，主要从事智能便携健康硬件的设计、研发、生产、销售及 服务。 根据公司三季报，2025年前三季度，公司实现营业收入5.52亿元。第三季度，实现营业收入1.67亿元，归母净利润-2951.33万元。 （文章来源：上海证券报） ...

#倍轻松及实控人马学军遭证监会立案#【倍轻松及实控人马学军涉嫌信息披露违法违规遭证监会立案】 #倍轻松及实控人马学军涉信披违法被立案#倍轻松公告称，公司及实际控制人马学军于2025年12月25日 收到中国证监会下发的《立案告知书》，因涉嫌信息披露违法违规，根据相关法律法规，中国证监会决 定对公司及实际控制人马学军立案。目前公司经营活动正常，立案调查期间将积极配合相关工作并履行 信息披露义务。(智通财经） 特此公告。 深圳市倍轻松科技股份有限公司董事会 2025 年 12月26日 ...